The active metabolite of the prodrug Moexipril.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aliskiren | The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Moexiprilat. |
| Allopurinol | The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Moexiprilat. |
| Aprotinin | Aprotinin may decrease the antihypertensive activities of Moexiprilat. |
| Azathioprine | The risk or severity of myelosuppression, anemia, and severe leukopenia can be increased when Moexiprilat is combined with Azathioprine. |
| Dapagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Moexiprilat. |
| Canagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Moexiprilat. |
| Ertugliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ertugliflozin is combined with Moexiprilat. |
| Empagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Moexiprilat. |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Moexiprilat. |
| Drospirenone | Moexiprilat may increase the hyperkalemic activities of Drospirenone. |
| Eplerenone | Eplerenone may increase the hyperkalemic activities of Moexiprilat. |
| Everolimus | The risk or severity of adverse effects can be increased when Everolimus is combined with Moexiprilat. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Moexiprilat. |
| Ardeparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Ardeparin. |
| Heparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Heparin. |
| Enoxaparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Enoxaparin. |
| Sulodexide | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Sulodexide. |
| Semuloparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Semuloparin. |
| Danaparoid | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Danaparoid. |
| Dalteparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Dalteparin. |
| Tinzaparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Tinzaparin. |
| Nadroparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Nadroparin. |
| Bemiparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Bemiparin. |
| Parnaparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Parnaparin. |
| Reviparin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Reviparin. |
| Icatibant | Icatibant may decrease the antihypertensive activities of Moexiprilat. |
| Lithium citrate | The serum concentration of Lithium citrate can be increased when it is combined with Moexiprilat. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be increased when it is combined with Moexiprilat. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be increased when it is combined with Moexiprilat. |
| Tizanidine | The risk or severity of hypotension can be increased when Tizanidine is combined with Moexiprilat. |
| Tolvaptan | Tolvaptan may increase the hyperkalemic activities of Moexiprilat. |
| Trimethoprim | Trimethoprim may increase the hyperkalemic activities of Moexiprilat. |
| Sodium aurothiomalate | The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Moexiprilat is combined with Sodium aurothiomalate. |
| Nicorandil | Nicorandil may increase the vasodilatory activities of Moexiprilat. |
| Sacubitril | The risk or severity of angioedema can be increased when Moexiprilat is combined with Sacubitril. |
| Ciprofloxacin | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Ciprofloxacin. |
| Iron | The risk or severity of adverse effects can be decreased when Iron is combined with Moexiprilat. |
| Icosapent | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Icosapent is combined with Moexiprilat. |
| Mesalazine | The risk or severity of renal failure can be increased when Mesalazine is combined with Moexiprilat. |
| Indomethacin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Moexiprilat. |
| Nabumetone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Moexiprilat. |
| Ketorolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Moexiprilat. |
| Tenoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Moexiprilat. |
| Celecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Moexiprilat. |
| Tolmetin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Moexiprilat. |
| Rofecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Moexiprilat. |
| Piroxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Moexiprilat. |
| Fenoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Moexiprilat. |
| Valdecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Moexiprilat. |
| Diclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Moexiprilat. |
| Sulindac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Moexiprilat. |
| Flurbiprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Moexiprilat. |
| Etodolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Moexiprilat. |
| Mefenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Moexiprilat. |
| Naproxen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Moexiprilat. |
| Sulfasalazine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Moexiprilat. |
| Phenylbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Moexiprilat. |
| Carprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carprofen is combined with Moexiprilat. |
| Diflunisal | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Moexiprilat. |
| Salicylic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Moexiprilat. |
| Meclofenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Moexiprilat. |
| Oxaprozin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Moexiprilat. |
| Ketoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Moexiprilat. |
| Balsalazide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Moexiprilat. |
| Ibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Moexiprilat. |
| Olsalazine | The risk or severity of renal failure can be increased when Olsalazine is combined with Moexiprilat. |
| Lumiracoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lumiracoxib is combined with Moexiprilat. |
| Magnesium salicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Moexiprilat. |
| Salsalate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Moexiprilat. |
| Choline magnesium trisalicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Choline magnesium trisalicylate is combined with Moexiprilat. |
| Antrafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antrafenine is combined with Moexiprilat. |
| Aminophenazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Moexiprilat. |
| Antipyrine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Moexiprilat. |
| Tiaprofenic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Moexiprilat. |
| Etoricoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Moexiprilat. |
| Taxifolin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Taxifolin is combined with Moexiprilat. |
| Oxyphenbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Moexiprilat. |
| Licofelone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Licofelone is combined with Moexiprilat. |
| Nimesulide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Moexiprilat. |
| Benoxaprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Moexiprilat. |
| Zomepirac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Moexiprilat. |
| Cimicoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Cimicoxib is combined with Moexiprilat. |
| Lornoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Moexiprilat. |
| Aceclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Moexiprilat. |
| Zaltoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Moexiprilat. |
| Azapropazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Moexiprilat. |
| Parecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Moexiprilat. |
| Salicylamide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Moexiprilat. |
| Kebuzone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Moexiprilat. |
| Isoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Moexiprilat. |
| Indoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indoprofen is combined with Moexiprilat. |
| Ibuproxam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuproxam is combined with Moexiprilat. |
| Floctafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Moexiprilat. |
| Fenbufen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Moexiprilat. |
| Etofenamate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Moexiprilat. |
| Epirizole | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Moexiprilat. |
| Benzydamine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benzydamine is combined with Moexiprilat. |
| Dexibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexibuprofen is combined with Moexiprilat. |
| Dexketoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexketoprofen is combined with Moexiprilat. |
| Droxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Moexiprilat. |